ライフサイエンスコーパス: half-life

1 short-lived (146)Sm-(142)Nd system (~100-My half-life).

2 ty for c-Myc and prolonged the oncoprotein's half-life.

3 onversion efficiency, and a long circulation half-life.

4 pecificity, insurmountable binding, or short half-life.

5 ate tail length, resulting in a greater mRNA half-life.

6 d was eliminated from the blood with a 2.5-h half-life.

7 egation of MEIOB and sharply reduced protein half-life.

8 on red blood cells (RBCs) improved the blood half-life.

9 results in a significant prolongation their half-life.

10 ssary for RBM24-based elevation of Sox2 mRNA half-life.

11 is could be the longer AB5075 ggt transcript half-life.

12 ed metabolic clearance and increased in vivo half-life.

13 g, but not VWFpp, were associated with FVIII half-life.

14 of relaxin is problematic because of a short half-life.

15 ltered CL and at the same time shortened its half-life.

16 eterodimerization with c-Jun increases c-Fos half-life.

17 elin-expressing tumors and has a short serum half-life.

18 mutations resulted in a decreased cagA mRNA half-life.

19 77)Lu voxel S values and an empirical kidney half-life.

20 n on thyroid uptake and whole-body effective half-life.

21 city is limited by rapid clearance and short half-life.

22 case constituent with an exceptionally short half-life.

23 at HPK1 down-regulates AXL and decreases its half-life.

24 nting a three- to fourfold increase in FVIII half-life.

25 ules with increased specificity and extended half-life.

26 omain-containing proteins and prolongs their half-life.

27 ng through AKT and GSK-3beta to increase MYC half-life.

28 d rapidly absorbed with a 14.5-hour terminal half-life.

29 (177)Lu voxel S values and an empiric kidney half-life.

30 2139-Ca monotherapy indicates a short HBsAg half-life (1.3 days) suggesting a rapid turnover of HBsA

31 (18)F (half-life, 110 min) labeling would result in a more prac

32 maleimide-NO2A and radiolabeled with (64)Cu (half-life, 12.7 h).

33 ts application has been limited by its short half-life (~13 h), which requires daily injections to ma

34 clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing.

35 on stainless steel, plastic, and nitrile for half-life 2.3-17.9 h.

36 The highest half-life (2.92/h) and lowest elimination rate (0.36/h)

37 OTR) in vitro with good selectivity and long half-life (24 h) in mice.

38 yridine-4,6(5H,7H)-dione), has a long plasma half-life (~ 24 hours) in mice, suggesting possible bind

39 An initial exponential decay phase with half-life 26 minutes was not correlated with outcome.

40 ressed early after infection and has a short half-life (~3 h) in HBV-infected PHH.

41 than that of its pentacene analogue (BPE-P, half-life, 33 h).

42 ned rapidly among HIV-infected participants (half-life; 39 years; 24-108 years; P = .001).

43 half-life = 55 d) than in the crude extract (half-life = 43 d) and their stability increased with the

44 pared to those administered 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2-6

45 enzylic oxidation resulted in a short plasma half-life (5 h) in human volunteers, and a backup progra

46 nins in CGA samples showed higher stability (half-life = 55 d) than in the crude extract (half-life =

47 of exogenous atRA by 70% and increased atRA half-life 6-fold.

48 This reveals rapid turnover (half-life ~7-10 h), which we confirmed by in vivo pulse-

49 stabilized analogues with an enhanced serum half-life(7).

50 ratio over 48 hours 1.67; parasite clearance half-life 8.67 h).

51 of the ephrin A2 receptor, long circulation half-life (8-12 h) in mouse plasma, a release rate depen

52 Plasma FVIII half-life after BIVV001 administration in mice and monke

53 existing methods of altering ligand binding half-life also change other potentially important biophy

54 However due to its short half-life and adverse side effects associated with syste

55 sion protein (CmAb-(IL10)(2)) to prolong its half-life and allow tumor-targeted delivery of IL-10.

56 d on the surface of EVs to investigate their half-life and biodistribution.

57 his effort is the modulation of autoantibody half-life and blocking access of autoantibodies to fragm

58 early Tmax, limited systemic exposure, long half-life and consequently a 2-fold accumulation over th

59 s in an approximately 21-day circulating IgG half-life and high plasma levels; similarly, FcRn recycl

60 partially effective due to short circulatory half-life and inefficient biodistribution.

61 apy (TAT) applications due to its attractive half-life and its 100% alpha-emission from nearly simult

62 lymphoblastic leukemia because of its longer half-life and lower immunogenicity.

63 3- and 26-fold increases in the RPV apparent half-life and mean residence time compared to native dru

64 o the clinic, taking advantage of the longer half-life and physical imaging properties of (18)F.

65 ular islatravir-triphosphate exhibits a long half-life and prolonged virological effects.

66 dant immunoglobulin isotype, has the longest half-life and protects against bacterial and viral infec

67 ed a new echinomycin formulation with longer half-life and significantly improved therapeutic effect.

68 endent lines of evidence including the short half-life and spontaneous activation of neutrophils, we

69 this compound suffered from a short in vivo half-life and suboptimal potency in whole blood.

70 It impacts protein half-life and therefore directs the actual presence of t

71 ch is likely to extend the compound's plasma half-life and thus assist in drug delivery into tumors.

72 bumin may serve to increase JMS-053's plasma half-life and thus extend the delivery of the compound t

73 Predicted infant dolutegravir half-life and time to protein adjusted-IC90 (0.064 mg/L)

74 DCP1A controls Tsix half-life and transcription elongation.

75 kdown increases beta-catenin levels, protein half-life and transcriptional activity.

76 Despite the uniquely long half-life and unprecedented basal nuclear localization o

77 CHIP binding affinity to Hsc70, CHIP protein half-life, and consequent clearance of stress-induced ub

78 s it is known to impact efficacy, stability, half-life, and immunogenicity.

79 onfined biodistribution, shorter circulatory half-life, and inability to communicate with the immune

80 ntly higher lung/blood C(max), AUC, extended half-life, and mean residence time in comparison to oral

81 However, its low stability, short half-life, and rapid inactivation by enzymes in physiolo

82 vity of VWF positively correlated with FVIII half-life, and the rare or low-frequency nonsynonymous V

83 ch as rapid drug metabolization, short serum half-life, and unspecific side effects.

84 turned for whole-body scintigraphy, thyroid, half-life, and whole-body half-life were significantly s

85 The long half-life appears to result in part from expansion and c

86 suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a stro

87 th a half-life that was up to four times the half-life associated with recombinant factor VIII, an in

88 PFBS showed the shortest half-life {average 44 d [95% confidence interval (CI): 3

89 is not significantly changed but whole-body half-life becomes longer in the hypothyroid group.

90 n be employed for various purposes, with the half-life being a crucial parameter to optimize for the

91 Also, RBM10 overexpression elongated p53's half-life by disrupting MDM2-p53 interaction and subsequ

92 rylation of PTPN22 at Ser(751) prolonged its half-life by inhibiting K48-linked ubiquitination and im

93 olylysine led to an increase in injected MSC half-life by more than an order of magnitude.

94 mice and substantially improves circulation half-life by protecting the antibody from an antigen sin

95 ce of production and degradation and measure half-life by quantifying the rate of decay after experim

96 Fc domains that confer a longer circulation half-life by virtue of more favorable pH-dependent bindi

97 vel fusion protein designed to overcome this half-life ceiling and maintain high sustained factor VII

98 d clearance, but it also subjects FVIII to a half-life ceiling of ~15 to 19 hours.

99 in vivo potency and a significantly extended half-life compared with anakinra.

100 decreased 34%, clearance increased 63%, and half-life decreased 41% comparing tesidolumab + IVIg to

101 The geometric mean parasite clearance half-life decreased by 11.6% (95% CI 3.4%-19.1%) in kelc

102 Half-life decreased with temperature and humidity increa

103 iption were strongly suppressed and its mRNA half-life decreased.

104 her demonstrate that claudin trafficking and half-life depend on carboxy-terminal sequences and that

105 This half-life discrimination is executed in the proximal sig

106 eral radiopharmaceuticals based on effective half-life distributions.

107 was more appropriate for capturing effective half-life distributions.

108 nd background-free quantification of in vivo half-life following administration to rabbits.

109 The parasite clearance half-life following artemether-lumefantrine treatment wa

110 The reaction kinetics and half-life for beta-carotene, lutein and alpha-tocopherol

111 ition coefficient (5.5% [95%CI 4.4-6.4]) and half-life for distribution plasma to CSF (2.1 h [1.3-2.9

112 95% confidence interval [CI], 4.5%-6.4%) and half-life for distribution plasma to CSF (2.1 hours; 95%

113 irectly contributes to a less-than-desirable half-life for the dental composite formulations currentl

114 challenging given a low serum stability and half-life for the native peptide.

115 Increasing recombinant FVIII (rFVIII) half-life further is ultimately dependent upon uncouplin

116 Competitor drugs with longer half-life further reduce the HD time.

117 However, limitations such as short half-life has hindered their usage.

118 d metabolism and systemic instability (short half-life) has hindered its therapeutic efficacy.

119 kinetics, modifications that increase plasma half-life have been revolutionary.

120 rapid renal clearance and short circulation half-life have prevented translation to clinical usefuln

121 ice, regardless of its much shorter reported half-life; however, adverse effects toward the placenta

122 development has been limited by their short half-life, immunogenicity and low membrane permeability,

123 FECD_REP tissue is elevated due to increased half-life in a corneal cells.

124 is leads to a rapid reduction in p53 protein half-life in an HDM2-dependent manner.

125 ted by the invasive administration and short half-life in blood circulation.

126 onical renin-angiotensin system, has a short half-life in blood.

127 y lower autoreactivity and prolonged in vivo half-life in huFcRn mice and rhesus macaques.

128 sirable to better match antibody circulation half-life in human and nonhuman primates.

129 monstrate its use to measure the circulation half-life in mice of two types of fluorescently labeled

130 mes in excess of the protein's characterized half-life in mouse and human embryonic fibroblasts.

131 WFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no corr

132 nt to O-glycosylate hOCN and to increase its half-life in plasma compared to wildtype hOCN.

133 also show that O-glycosylation increases OCN half-life in plasma ex vivo and in the circulation in vi

134 kidneys and liver and has a short effective half-life in plasma, which could limit its use in vivo.

135 moderate selectivity to EP2, a short plasma half-life in rodents (1.7 h) and low aqueous solubility

136 d t1/2 (absence of light), indicating longer half-life in the absence of light.

137 2 diabetes (T2D), but its short circulation half-life in the blood requires two injections per day t

138 Whole-body half-life in the hypothyroid group was significantly lon

139 accompanying side effects and its very short half-life in vivo.

140 been difficult to assess owing to its short half-life in vivo.

141 on hematocrit, but this protein has a short half-life in vivo.

142 ng various biomaterials that can prolong the half-life, increase storage duration and control the rel

143 efinitely among HIV-uninfected participants (half-life, infinity; 95% confidence interval, 309 years

144 nverting small differences in ligand binding half-life into large changes in cell signaling.

145 lysis of blood concentration and circulation half-life is an important consideration for any intraven

146 and transport protein whose long circulatory half-life is facilitated by engagement with the human ce

147 VT carriage prevalence half-life is similar among PCV-vaccinated and PCV-unvacc

148 howed that indeed the ligand-TCR interaction half-life is the decisive factor for activating downstre

149 However, it is labeled with the short half-life isotope (11)C.

150 erse biological processes, including protein half-life, localization, and interaction.

151 We now report that pironetin has a short half-life (<7 min) in human liver microsomes, suggesting

152 However, immunogenicity and a short serum half-life may limit the ability of immunotoxins to trans

153 -rat embryonic fibroblasts (NEFs) exhibits a half-life more than ten times in excess of the protein's

154 An estimated half-life of >945 h was obtained for bisporphyrin-fused

155 The biologic half-life of (131)I-GMIB-anti-HER2-VHH1 in healthy subje

156 ptide receptor radionuclide therapy, and the half-life of (64)Cu would also facilitate good-manufactu

157 Because of the favorable half-life of (64)Cu, tracers labeled with this PET nucli

158 However, the short half-life of (68)Ga (68 min) creates problems with manuf

159 tment model with an initial fast compartment half-life of 0.14 h and a subsequent slow compartment ha

160 ighly metabolically stable with a biological half-life of 10.5 h, suggesting a once-daily dosing regi

161 injection without adverse effects, a plasma half-life of 113 h in minipigs after intravenous injecti

162 Ra-226 is the major component of NORM with a half-life of 1600 years that is present at concentration

163 is a naturally occurring radionuclide with a half-life of 1600 years.

164 (188)Re takes merely 1 hour, compared to its half-life of 17 hours.

165 the positive CFG decreases the fragmentation half-life of 2,5-dimethyl-tetrazole in refluxing o-xylen

166 uch product is (60)Fe, a radionuclide with a half-life of 2.6 My that is predominantly produced in ma

167 d to decay spontaneously in the dark, with a half-life of 210 min, to p-aminophenylnitrene and amino-

168 antum-mechanical tunneling with an effective half-life of 22 min at 3 K.

169 mAb114 has linear pharmacokinetics and a half-life of 24.2 days (standard error of measurement 0.

170 mainder being long lived and decaying with a half-life of 2690 days (95% CrI 1016-15 078).

171 duced by nuclear fission reactions and has a half-life of 29 years; each of these radionuclides poses

172 Indoxacarb dissipated with half-life of 3.12-3.21 and 1.24-1.35d for tomato and soi

173 ant was 0.02 +/- 0.06 min-1, equivalent to a half-life of 31.6 minutes.

174 ng at 80 K is 0.16 s(-1), corresponding to a half-life of 4.3 s, and indicating that bond shifting is

175 The reservoir has an estimated half-life of 44 mo and is largely composed of clones of

176 999) and determined CAB apparent elimination half-life of 47 days.

177 l RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased o

178 of 0.14 h and a subsequent slow compartment half-life of 5.2 h, consistent with reversible protein b

179 assemblies to have a substantial circulation half-life of 5.6 h and to undergo renal clearance-charac

180 ver 5100 cd/m(2) at 489 nm, and an operating half-life of 51 min at 1500 cd/m(2).

181 known for its short half-life, we found the half-life of 6A4 to be approximately 6 days in mice, thu

182 Because (89)Zr has a half-life of 78 hours, only a single administration of t

183 C6 HAT exhibits a half-life of 789 years in solution.

184 roved EQE of 5.2% at 479 nm and an operating half-life of 90 min at 100 cd/m(2).

185 a 1.3-fold increase in the blood circulatory half-life of a high hFcRn-binding triple-thiol variant c

186 ort the ability of p62/SQSTM1 to extend mRNA half-life of a spectrum of pro-metastatic factors.

187 ) complex resulted to be more stable, with a half-life of about 10 min.

188 d EGFR2 (HER2) signaling, SHP2 increases the half-life of activated Ras by blocking recruitment of Ra

189 Nano-mupirocin exhibited prolonged half-life of active antibiotic and displayed superior an

190 Storage studies to estimate the half-life of anthocyanin in the microcapsule at room tem

191 sure the blood concentration and circulation half-life of any fluorescently labeled agent using only

192 antigen sink was saturated by 5F9, and a 5F9 half-life of approximately 13 days was observed.

193 ant was 0.29 +/- 0.09 min-1, equivalent to a half-life of approximately 2.4 minutes.

194 anchoring molecule increased the intraocular half-life of bevacizumab from 5.8 days to over 18 days a

195 The geometric mean half-life of BIVV001 was three to four times as long as

196 ssay revealed that EMD tended to shorten the half-life of c-Myc by approximately half.

197 Although the long plasma half-life of CAB-LA is an important attribute for PrEP,

198 etric method is not constrained by the short half-life of carbon-11 and is an attractive alternative

199 ion of the kynurenine pathway, but the short half-life of carbon-11 limits its application.

200 so needs to be very rapid owing to the short half-life of carbon-11.

201 The geometric mean half-life of CBDA was 14.1 h.

202 nd P123 showed a significant increase in the half-life of citral compared to that in its individual c

203 Though the blood elimination half-life of contrast agents is about 90 minutes, recent

204 lood-brain barrier penetration, and low drug half-life of current regimens.

205 (1)O(2) in surface waters, the environmental half-life of DA due to singlet oxygen-induced transforma

206 YTHDF2 decreases the half-life of diverse m(6)A transcripts that contribute t

207 The half-life of ELKS is on the timescale of days and not we

208 onstrate that nanoencapsulation improves the half-life of encapsulated cGAMP by 40-fold, allowing for

209 , foam overrun, microstructure, rheology and half-life of foam.

210 The mean (standard deviation) half-life of HBsAg in blood was 6.7 (5.5) days, which re

211 In addition, ANKDD1A decreases the half-life of HIF1alpha by upregulating FIH1, decreases g

212 hanism to prevent degradation and extend the half-life of IgG and albumin in the circulation.

213 In mice, the bioavailability and half-life of IL-2 in vivo can be increased by complexing

214 The presence of linc-SPRY3-2/3/4 reduced the half-life of known IGF2BP3 binding mRNA, such as the ant

215 and correlated with an increased circulating half-life of Lyn-deficient pMos.

216 r gene regulation and accounts for the short half-life of many transcription factors.

217 ining the significantly (p <0.001) increased half-life of MIG6 from 1.6 +/- 0.2 h under control condi

218 BP) matrix at low temperatures, and it has a half-life of more than 2 weeks at ambient conditions in

219 These findings show that prolonging the half-life of Nkx3.1 reduces proliferation, enhances DNA

220 The estimated half-life of occupancy disappearance was ~100 min.

221 information recall, which extrapolates to a half-life of over 15 years at 25 degrees C.

222 therapy-resistant phenotype, stabilizes the half-life of p53 and uses p53 to initiate a slow-cycling

223 s a novel target to significantly reduce the half-life of pathogenic antibodies or extend the half-li

224 Although the half-life of PEG~TLZ and released TLZ in the mouse was o

225 One approach to extending the half-life of pharmacologically active small molecules is

226 PINK1, and BAG6 overexpression decreased the half-life of PINK1.

227 The half-life of recombinant factor VIII ranges from 15 to 1

228 on and used mixed effects models to estimate half-life of responses in four human clinical trials.

229 s are comparable to those of APOBEC3G with a half-life of roughly 6 h postinfection, demonstrating th

230 SMALL RNA DEGRADING NUCLEASE 1 shortens the half-life of several miRNAs in de-etiolated seedlings.

231 lver is reportedly excreted in the bile, the half-life of silver was comparable in all ages and plasm

232 biquitin ligases, recognize and regulate the half-life of specific proteins on the basis of their N-t

233 The elimination half-life of SRF was also increased by 2-fold and the me

234 The short half-life of SS1P is due to its very rapid filtration by

235 ance of red blood cells while increasing the half-life of that response, leading to the maximal respo

236 ides is unfavorable, the extended biological half-life of the GB1107 surrogate indicated that systemi

237 The half-life of the knocked-in transcript was shorter than

238 solubility in both models and increased the half-life of the mutant pVHL proteins in the cell cultur

239 We determined that the long half-life of the naked mole-rat p53 protein reflects pro

240 Which route is preferred depends on the half-life of the protein in question.

241 rogated or depleted at a rate defined by the half-life of the protein.

242 The half-life of the translational D. indicum metI RNA-SAM c

243 T (porA) resulted in a shortened transcript half-life of the upstream gfp or porA gene, indicating t

244 -life of pathogenic antibodies or extend the half-life of therapeutic monoclonals.

245 of patients with hemophilia A, but the short half-life of these products affects the patients' qualit

246 The mean half-life of TY014 was approximately 12.8 days.

247 AFM13 in the combination setting revealed a half-life of up to 20.6 hours.

248 id decreased PRPP synthetase activity with a half-life of ~ 8 h, and combining cisplatin and amino ac

249 omal encapsulation resulted in a circulation half-life of ~2 h in vivo (compared to reported circulat

250 Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved

251 stant to RNase-catalyzed degradation, with a half-life of ~5 days in rat cerebrospinal fluid or serum

252 pendent rate constants (k~1.4x10(-3) s(-1) ; half-life of ~8 min) were measured from 10 to 20 K.

253 pHLIP ICG exhibits a multi-hour circulation half-life, offering protracted delineation of vasculatur

254 The greater dependency of parasite clearance half-life on parasite age in artemisinin resistant infec

255 did not alter FcgammaRIIIa or FcRn binding, half-life, or their ability to deplete target cells in F

256 molecules or induced effectors having a long half-life, particularly in specific cell types.

257 nt efficacy by evaluating parasite clearance half-life, pfkelch13, and other (pfdhfr, pfdhps, pfmdr1,

258 both RSSH and COS is tunable with respect to half-life, pH, and availability of thiols.

259 0.8) and low average errors (<factor of 3 in half-life predictions) and were robust in cross-validati

260 ncentration (C(max)) predictions; and 70% of half-life predictions] are accurate to within twofold.

261 ons peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased

262 t promise to address these issues: improving half-life, reducing immunogenicity and enabling intracel

263 f a posttranscriptional hub involved in mRNA half-life regulation of cancer-related transcripts.

264 the physiological significance of its short half-life remains unclear.

265 he bicyclic peptide extended its circulating half-life, resulting in increased tumor signals (36%ID/g

266 a dose-dependent manner and shortened STAT2 half-life significantly from approximately 30 to 5 h.

267 isotope with high positron yield and a long half-life suitable for imaging at delayed time points.

268 which are expected to translate into a human half-life suitable for once-weekly dosing.

269 GB001 was well tolerated, with the estimated half-life supporting once-daily (QD) dosing.

270 In addition, shortened erythrocyte half-life, suppressed erythropoietin response to anemia,

271 pseudo first order kinetics, with increasing half-life ( t(1/2)) in the order of toluene ( t(1/2) = 4

272 ls, 2 was found to exhibit a pharmacokinetic half-life ( T(1/2)) longer than that of 1, as well as a

273 Fipronil dissipated with half-life (T(1/2)) of 2.8-4.3 days while for total fipro

274 ons (T(max)) in 2.50-4.17 h; the mean plasma half-life (t(1/2)) was 23.5-28.4 h.

275 Median serum HBsAg half-life (t(1/2)) was estimated as 1.3 [0.9-1.8] days c

276 inetics, measured by apparent terminal phase half-life (t(1/2app)) and estimated time to lower limit

277 ha did not destabilize the Fbxl2 transcript (half-life [t (1/2)], ~10 h) but inhibited SP1 transactiv

278 anner, reaching steady-state by day 8 with a half-life (t1/2) from 16.3 to 19.2 hours.

279 that HN3-ABD-T20 had a 45-fold higher serum half-life than HN3-T20 (326 minutes vs. 7.3 minutes); co

280 ab is a monoclonal antibody with an extended half-life that is being developed to protect infants for

281 iments indicated that cytoplasmic Cx43 had a half-life that was 50% shorter than membrane-associated

282 ustained factor VIII activity levels, with a half-life that was up to four times the half-life associ

283 However, skin infection decreased Mphi half-life, thereby limiting the duration of memory.

284 e emerging strategy is to increase clearance half-life through enhanced binding to serum albumin.

285 ramidates of proline hydrolyzed fast, with a half-life time as short as 2.4 h for Pro-AMP in ethylimi

286 Mean plasma half-life was 27.3 min with primarily renal clearance (m

287 kinetics were dose proportional; the average half-life was 5.5 days.

288 The islatravir-triphosphate intracellular half-life was 78.5-128.0 h.

289 The half-life was about 2 weeks.

290 The antibody half-life was estimated to decrease from 32 months (95%

291 Inferior graft half-life was observed in KALT versus KTA recipients wit

292 ation between Gal exposure and estimated VWF half-life was observed in those patients with enhanced V

293 In addition, NHE3 half-life was reduced accounting for decreased NHE3 prot

294 Within this group, whole-body half-life was significantly shorter in the rhTSH treatme

295 TFV-DP median half-life was ten days (IQR:7, 12) in pregnancy and 17 d

296 While naloxone is known for its short half-life, we found the half-life of 6A4 to be approxima

297 In vivo blood half-life (weighted, 7.03 min) and octanol/water phase p

298 tigraphy, thyroid, half-life, and whole-body half-life were significantly shorter in the rhTSH groups

299 Klotho transcription and diminished protein half-life, whereas cleavage by ADAM proteases was not mo

300 sion reduces beta-catenin levels and protein half-life, whereas FBXW2 knockdown increases beta-cateni